{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:04:03Z","timestamp":1788537843426,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alveolar soft part sarcoma (ASPS) is an extremely rare neoplasm that often presents with metastatic disease at diagnosis, leading to a poor prognosis. Conventional chemotherapy is generally ineffective against ASPS. Recent studies, nonetheless, suggest that tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) may be effective treatment options.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case<\/jats:title><jats:p>We present a seven\u2010year\u2010old girl with stage IV ASPS in whom initial therapy with pazopanib, a TKI, had resulted in significant gastrointestinal side effects and poor drug compliance. We switched her treatment to an ICI regimen, a combination of nivolumab and ipilimumab, which led to a complete response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the value of ICIs as potential treatment options for ASPS in the pediatric population, especially in patients who cannot tolerate TKIs' side effects.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.70305","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T09:36:24Z","timestamp":1755336984000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven\u2010Year\u2010Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-0094","authenticated-orcid":false,"given":"Aziz","family":"Eghbali","sequence":"first","affiliation":[{"name":"Clinical Research Development Center of Aliasghar Hospital Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-0041","authenticated-orcid":false,"given":"Mobin","family":"Obeidinia","sequence":"additional","affiliation":[{"name":"Research Scholar, Gastrointestinal and Liver Diseases Research Center, Firoozgar General Hospital Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1447-8944","authenticated-orcid":false,"given":"Hamideh Sadat","family":"Mirmohammadi","sequence":"additional","affiliation":[{"name":"Clinical Research Development Center of Aliasghar Hospital Iran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-8798","authenticated-orcid":false,"given":"Roghayeh","family":"Rahimiafazal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Shahid Beheshti University of Medical Sciences, Mofid Children Hospital  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4878-3721","authenticated-orcid":false,"given":"Arya","family":"Shirani","sequence":"additional","affiliation":[{"name":"Cardiology Resident, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy096"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026805"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad102"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-022-01505-x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26953"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0161"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30153-6"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100407"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000571"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.006"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09968-5"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4490"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000071199"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.007"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1249093"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00264-8"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"issue":"6","key":"e_1_2_12_19_1","article-title":"Complete Response to Pembrolizumab in Stage IV Alveolar Soft Part Sarcoma After Failure of Four Lines of Treatment: A Case Report and Literature Review","volume":"16","author":"Aijaz P.","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2018.05.013"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.49174"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7154"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2017.009993"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120257"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00385"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0037"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2164"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30671-0"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T02:58:36Z","timestamp":1757127516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/cnr2.70305"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70305","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70305"}}